Enanta Pharmaceuticals (NASDAQ: ENTA) posts results for quarter ended June 30, 2025

Rhea-AI Filing Summary

Enanta Pharmaceuticals, Inc. filed a Form 8-K to report that it has announced its financial results for the fiscal quarter ended June 30, 2025. On August 11, 2025, the company issued a press release with these quarterly results and furnished that release as Exhibit 99.1. The filing is primarily administrative, directing readers to the press release for detailed financial information, and is signed on behalf of the company by President and Chief Executive Officer Jay R. Luly, Ph.D.

false000117764800011776482025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35839	04-3205099
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4 Kingsbury Avenue
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ENTA		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release of Enanta Pharmaceuticals, Inc. dated August 11, 2025, reporting Enanta's financial results for the fiscal quarter ended June 30, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			ENANTA PHARMACEUTICALS, INC.
Date:	August 11, 2025	By:	/s/ Jay R. Luly, Ph.D.
			Jay R. Luly, Ph.D. President and Chief Executive Officer

FAQ

What did Enanta Pharmaceuticals (ENTA) disclose in this Form 8-K?

Enanta Pharmaceuticals, Inc. reported that it announced its financial results for the fiscal quarter ended June 30, 2025, and furnished the related press release as Exhibit 99.1.

Which period do the reported Enanta (ENTA) results cover?

The results discussed in this Form 8-K cover Enanta Pharmaceuticals' fiscal quarter ended June 30, 2025.

What is Exhibit 99.1 in Enanta Pharmaceuticals' 8-K filing?

Exhibit 99.1 is the press release of Enanta Pharmaceuticals, Inc. dated August 11, 2025, reporting the company's financial results for the fiscal quarter ended June 30, 2025.

Does this Enanta (ENTA) 8-K include detailed financial statements?

The Form 8-K itself refers readers to Exhibit 99.1, a press release, for Enanta Pharmaceuticals' detailed financial results for the fiscal quarter ended June 30, 2025.

Who signed the Enanta Pharmaceuticals Form 8-K reporting quarterly results?

The Form 8-K was signed on behalf of Enanta Pharmaceuticals, Inc. by Jay R. Luly, Ph.D., the company's President and Chief Executive Officer.

On which exchange is Enanta Pharmaceuticals' common stock listed and under what symbol?

Enanta Pharmaceuticals' common stock, par value $0.01 per share, is listed on the Nasdaq Global Select Market under the trading symbol ENTA.